4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $35,084 | -31.4% | 2,756 | -2.7% | 0.00% | – |
| Q2 2023 | $51,174 | -44.7% | 2,832 | -47.4% | 0.00% | – |
| Q1 2023 | $92,620 | -84.5% | 5,388 | -80.0% | 0.00% | – |
| Q4 2022 | $597,493 | -74.2% | 26,902 | -90.7% | 0.00% | – |
| Q3 2022 | $2,317,000 | -52.6% | 288,204 | -58.9% | 0.00% | – |
| Q2 2022 | $4,889,000 | -70.4% | 700,452 | -35.8% | 0.00% | -100.0% |
| Q1 2022 | $16,499,000 | -34.0% | 1,091,218 | -4.3% | 0.00% | -50.0% |
| Q4 2021 | $25,016,000 | -9.2% | 1,140,175 | +11.6% | 0.00% | 0.0% |
| Q3 2021 | $27,562,000 | +10.3% | 1,021,973 | -1.5% | 0.00% | 0.0% |
| Q2 2021 | $24,988,000 | -55.3% | 1,037,726 | -19.4% | 0.00% | -60.0% |
| Q1 2021 | $55,854,000 | -15.5% | 1,287,571 | -19.2% | 0.01% | -16.7% |
| Q4 2020 | $66,086,000 | – | 1,594,355 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |